Related Experiment Video
Updated: May 28, 2025
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
21.3K
Glycosylated Delphinidins Decrease Chemoresistance to Temozolomide by Regulating NF-κB/MGMT Signaling in Glioblastoma
Diego Carrillo-Beltrán1,2,3, Yessica Nahuelpan1, Constanza Cuevas1,2
1Laboratorio de Virología Molecular, Instituto de Bioquímica y Microbiología, Facultad de Ciencias, Universidad Austral de Chile, Valdivia 5090000, Chile.
Cells
|February 12, 2025
Summary
Delphinidins, natural compounds from berries, show promise in treating glioblastoma (GB). Delphinidin 3 glucoside synergizes with temozolomide (TMZ) to overcome chemoresistance by inhibiting NF-κB signaling.
Area of Science:
- Oncology
- Pharmacology
- Natural Products Chemistry
Background:
- Glioblastoma (GB) is an aggressive brain tumor with poor prognosis and significant resistance to chemotherapy, notably temozolomide (TMZ).
- Mechanisms of TMZ resistance include DNA repair enzyme MGMT expression and the presence of glioblastoma stem cells (GSCs).
- Natural compounds, such as delphinidins found in berries, are emerging as potential therapeutic agents due to their anti-cancer properties.
Purpose of the Study:
- To investigate the potential of glycosylated delphinidins as adjuvant therapy for glioblastoma.
- To evaluate the efficacy of specific delphinidin derivatives, delphinidin 3,5 di-glucoside and delphinidin 3 glucoside, against glioblastoma cells.
- To explore the role of delphinidins in overcoming temozolomide resistance by targeting NF-κB signaling.
Main Methods:
- In vitro assessment of delphinidin 3,5 di-glucoside and delphinidin 3 glucoside on glioblastoma cell viability.
- Evaluation of synergistic effects between delphinidin 3 glucoside and temozolomide (TMZ).
- Analysis of NF-κB signaling pathway inhibition by delphinidin 3 glucoside.
Main Results:
- Delphinidin 3,5 di-glucoside demonstrated potent anticancer effects as a standalone agent.
- Delphinidin 3 glucoside exhibited synergy with TMZ, significantly reducing glioblastoma cell viability.
- Delphinidin 3 glucoside provided rapid and sustained inhibition of NF-κB signaling.
Conclusions:
- Glycosylated delphinidins, particularly delphinidin 3 glucoside, represent a promising natural strategy to enhance glioblastoma treatment.
- Delphinidin 3 glucoside shows potential as an adjuvant therapy to overcome TMZ resistance.
- Targeting NF-κB signaling with delphinidins offers a novel approach for glioblastoma therapy.
